OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Update on MRD Testing in Acute Lymphoblastic Leukemia

home / peer-exchange / mrd-testing-in-all
Advertisement
Prognostic Factors in Acute Lymphoblastic Leukemia

EP. 1: Prognostic Factors in Acute Lymphoblastic Leukemia

February 1st 2020
Considering Induction Regimens for ALL

EP. 2: Considering Induction Regimens for ALL

February 1st 2020
Induction Strategies for Philadelphia-Positive ALL

EP. 3: Induction Strategies for Philadelphia-Positive ALL

February 1st 2020
ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

EP. 4: ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

February 1st 2020
Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

EP. 5: Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

February 1st 2020
MRD in ALL: Prognostic Importance and Multidisciplinary Care

EP. 6: MRD in ALL: Prognostic Importance and Multidisciplinary Care

February 1st 2020
Advertisement
ALL: When and Who to Test for Minimal Residual Disease

EP. 7: ALL: When and Who to Test for Minimal Residual Disease

February 1st 2020
Strategies to Assess Minimal Residual Disease

EP. 8: Strategies to Assess Minimal Residual Disease

February 1st 2020
Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

EP. 9: Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

February 1st 2020
MRD's Impact on Subsequent Therapy Choice in ALL

EP. 10: MRD's Impact on Subsequent Therapy Choice in ALL

February 1st 2020
MRD+ ALL: Evolving Role of BiTE Therapy

EP. 11: MRD+ ALL: Evolving Role of BiTE Therapy

February 1st 2020
Optimizing Use of Maintenance Therapy in ALL

EP. 12: Optimizing Use of Maintenance Therapy in ALL

February 1st 2020
Advertisement
Future Directions for MRD Testing in ALL

EP. 13: Future Directions for MRD Testing in ALL

February 1st 2020
MRD Testing in Hematologic Malignancies Other Than ALL

EP. 14: MRD Testing in Hematologic Malignancies Other Than ALL

February 1st 2020
Acute Lymphoblastic Leukemia: Future Directions in Therapy

EP. 15: Acute Lymphoblastic Leukemia: Future Directions in Therapy

February 1st 2020

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact